x
ServiziMenu principaleHome
Facebook Twitter Linkedin Print
Home > Studi clinici > Protocolli 2024 - in attivazione

Protocolli GOIRC-sponsored in attivazione

GOIRC-08-2018 – CABOGEN (OSSERVAZIONALE)

Retrospective analysis of patients with metastatic renal cell carcinoma treated with CABOzantinib: a GENomic signature for describing long-term response

Centro Coordinatore: Reggio Emilia

 

GOIRC-01-2022  HEROS (OSSERVAZIONALE)

HER2 aberrations in advanced NSCLC: an Observational, retrospective and prospective, multi-centric Study exploring HER2 alterations incidence and therapeutic management in Italy

Centro Coordinatore: Parma

 

GOIRC-01-2023  CARRY-ON

Continued PD-L1 inhibition with atezolizumab with rechallenge chemotherapy in patients with sensitive relapse SCLC progressing on first-line platinum-etoposide chemotherapy and a PD-L1 inhibitor – CARRY ON study

Centro Coordinatore: Bologna

 

GOIRC-01-2024  PRELUDE

Pembrolizumab plus lenvatinib in REcurrent ccRCC patients failing permbroLizUmab aDjuvant treatment - PRELUDE Trial

Centro Coordinatore: Terni

 

Apri